Trials / Completed
CompletedNCT02247401
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.
Detailed description
Non-cirrhotic subjects were directly enrolled into Arm A. Cirrhotic subjects were randomized to either Arm B (12 weeks of treatment) or Arm C (24 weeks of treatment).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 2 DAA | ABT-450/r/ABT-267 tablets |
| DRUG | RBV | Ribavirin tablets |
Timeline
- Start date
- 2014-11-04
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2014-09-25
- Last updated
- 2021-07-30
- Results posted
- 2017-07-27
Source: ClinicalTrials.gov record NCT02247401. Inclusion in this directory is not an endorsement.